|
Click here to view online. Add this email to your safelist. |
|||||||||||
|
|
|||||||||||
|
AstraZeneca presents data at ASN Kidney Week 2022 reinforcing urgent need for early screening of chronic kidney disease and the benefits of earlier treatment initiation for patients and healthcare systems |
|||||||||||
|
|
|||||||||||
|
5 November 2022
AstraZeneca, a leader in cardiorenal research, presented new data at the American Society of Nephrology (ASN) Kidney Week 2022 in Orlando, Florida, US on the importance of earlier screening and diagnosis of chronic kidney disease (CKD) and the impact of Farxiga on reducing healthcare costs. These findings were also simultaneously published in the Journal of the American Society of Nephrology. |
|||||||||||
|